Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

NEW YORK – RedHill Biopharma this week said it plans to launch a Phase II trial evaluating an investigational Crohn's disease drug in a biomarker-defined population, pending discussions with the US ...

NEW YORK – The European Commission on Friday expanded approval of Bristol Myers Squibb's CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) as a third-line treatment for adult patients with ...

The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.